NDA 021192 · Sandoz
Lescol Xl
Fluvastatin Sodium · Oral
Last checked: Nov 19, 2026Latest source record: Nov 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Oct 6, 2000
Approved uses
4
Original approval plus efficacy supplements
Registered trials
67
15 Phase 3, 4 recruiting
FAERS reports
4,471
3,641 serious, 462 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 31, 2024.
Fluvastatin sodium extended-release tablets are indicated: • To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg of fluvastatin daily. Fluvastatin sodium extended-release tablets are indicated ( 1 ): • To reduce the risk of undergoing coronary revascularization procedures and slow the progression of coronary atherosclerosis in adults with clinically evident coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia. • As an adjunct to diet to reduce LDL-C in adults and pediatric patients 10 years of age and older with heterozygous familial hypercholesterolemia (HeFH) who require 80 mg
Mechanism: Fluvastatin is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of cholesterol.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 10, 2006 Supplement 11 · Efficacy · priority review LetterLabel
- Apr 10, 2006 Supplement 10 · Efficacy LabelLetter
- May 27, 2003 Supplement 5 · Efficacy LabelLetter
- Oct 6, 2000 Original approval · Type 3 - New Dosage Form ReviewLabelLetter
1 products under this application
- LESCOL XL · FLUVASTATIN SODIUM EQ 80MG BASE · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluvastatin" as an intervention, any sponsor and status, largest first.
- A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on StatinPivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01492361 · 8,179 participants · Start Nov 2011 · Primary completion May 2018
Drug: AMR101; Placebo and 1 more · For: Cardiovascular Diseases
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 410 sites in all
- Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCIPivotal-lookingCompleted
Peking University First HospitalAcademic, hospital or other
NCT01293097 · 2,884 participants · Start Jun 2010 · Primary completion Oct 2011
Drug: Atorvastatin; Statin · For: Non-ST Segment Elevation Myocardial Infarction; Unstable Angina Pectoris; Stable Angina Pectoris
Sites: Beijing, China
- Statin Recapture Therapy Before Coronary Artery Bypass GraftingPivotal-lookingCompleted
University of CologneAcademic, hospital or other
NCT01715714 · 2,630 participants · Start Nov 7, 2012 · Primary completion Apr 24, 2019
Drug: Statin Recapture Therapy; Placebo · For: Coronary Artery Disease
Sites: Freiburg im Breisgau, Germany; Bad Neustadt an der Saale, Germany; Aachen, Germany · 10 sites in all
- Fluvastatin in the Therapy of Acute Coronary SyndromePivotal-lookingCompleted
NovartisNovartis (NVS)
NCT00171275 · 1,000 participants · Start Nov 2003 · Primary completion Feb 2007
Drug: Fluvastatin · For: Coronary Disease; Myocardial Infarction
Sites: Prague, Czechia
- Acetaminophen or Fluvastatin Compared to Placebo on the Transient Post-Dose Symptoms (PDS) Following an Intravenous (i.v.) Infusion of a Single Dose of Zoledronic Acid 5mg, in Post-menopausal Women With Low Bone MassPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00489424 · 793 participants · Start Jun 2007 · Primary completion Dec 2007
Drug: Placebo; Acetaminophen and 1 more · For: Osteoporosis
Sites: Http://www.osteoporosisclinicalresearch.com, New Jersey
- Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)Pivotal-lookingCompleted
Amarin Pharma Inc.Industry
NCT01047501 · 702 participants · Start Dec 2009 · Primary completion Feb 2011
Drug: AMR101 (ethyl icosapentate) - 4 g/day; AMR101 (ethyl icosapentate) - 2 g/day and 1 more · For: Hypertriglyceridemia
Sites: Muscle Shoals, Alabama; Scottsboro, Alabama; Phoenix, Arizona · 80 sites in all
NovartisNovartis (NVS)
NCT00664742 · 614 participants · Start Sep 2006 · Primary completion Oct 2007
Drug: Fluvastatin XL® · For: Metabolic Syndrome
Sites: Istanbul, Turkey (Türkiye)
- StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled TrialPivotal-lookingNot yet recruiting
Prof. dr. Nathalie van der VeldeAcademic, hospital or other
NCT06785727 · 612 participants (planned) · Start Feb 1, 2025 · Primary completion Dec 1, 2028
Drug: Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin) · For: Ischemic Stroke; Transient Ischemic Attack
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea319
- myalgia317
- dizziness298
- fatigue280
- diarrhoea255
- drug ineffective253
- dyspnoea250
- asthenia243
- myocardial infarction221
- fall211
- vomiting207
- arthralgia201
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 359 |
| 2005 | 422 |
| 2006 | 355 |
| 2007 | 238 |
| 2008 | 232 |
| 2009 | 257 |
| 2010 | 259 |
| 2011 | 351 |
| 2012 | 254 |
| 2013 | 165 |
| 2014 | 179 |
| 2015 | 192 |
| 2016 | 182 |
| 2017 | 145 |
| 2018 | 167 |
| 2019 | 126 |
| 2020 | 117 |
| 2021 | 132 |
| 2022 | 108 |
| 2023 | 64 |
| 2024 | 93 |
| 2025 | 40 |
| 2026 | 34 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jan 27, 2026
Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-31). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jan 27, 2026
Fluvastatin Sodium, Tablet, Extended Release, 80 mg (NDC 0781-8017-01). Discontinuation of the manufacture of the drug
To Be Discontinued · updated Jan 27, 2026
Lescol XL, Tablet, Extended Release, 80 mg (NDC 66758-211-31). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lescol XL (Fluvastatin Sodium)
2024 spending
$527K
Beneficiaries
165
616 claims
Per beneficiary
$3,195
$12.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $888,261 |
| 2021 | $962,166 |
| 2022 | $865,926 |
| 2023 | $722,048 |
| 2024 | $527,126 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Interaction potential between clarithromycin and individual statins-A systematic review.
Hougaard Christensen MM, Bruun Haastrup M, Øhlenschlaeger T, et al. · Basic Clin Pharmacol Toxicol 2020 · Comparative Study, Systematic Review
- Comparative Lipid-Lowering/Increasing Efficacy of 7 Statins in Patients with Dyslipidemia, Cardiovascular Diseases, or Diabetes Mellitus: Systematic Review and Network Meta-Analyses of 50 Randomized Controlled Trials.
Zhang X, Xing L, Jia X, et al. · Cardiovasc Ther 2020 · Network Meta-Analysis, Systematic Review
- Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
· Lancet 2026 · Meta-Analysis
- Genetic markers associated with long-term cardiovascular outcome in kidney transplant recipients.
Pihlstrøm HK, Mjøen G, Mucha S, et al. · Am J Transplant 2019 · Multicenter Study, Randomized Controlled Trial
- Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, et al. · Cochrane Database Syst Rev 2023 · Systematic Review, Meta-Analysis
- Pitavastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Wright JM · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Novartis
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.